What are the differences between malignant hyperthermia and neuroleptic malignant syndrome regarding triggers, clinical presentation, and treatment?

Malignant Hyperthermia vs Neuroleptic Malignant Syndrome

Malignant hyperthermia (MH) is a pharmacogenetic crisis triggered by volatile anesthetics and succinylcholine during general anesthesia, while neuroleptic malignant syndrome (NMS) is an idiosyncratic reaction to dopamine antagonists (antipsychotics) that develops over hours to days—the key distinguishing features are trigger exposure, onset timing, and genetic basis.

Triggers

Malignant Hyperthermia:

• Volatile inhalational anesthetics (halothane, desflurane, sevoflurane, isoflurane)
• Succinylcholine (depolarizing neuromuscular blocker)
• Occurs exclusively during or immediately after general anesthesia 1

Neuroleptic Malignant Syndrome:

• Typical and atypical antipsychotics (dopamine antagonists)
• Antiemetics with dopamine-blocking properties (droperidol, metoclopramide)
• Can occur at any point during treatment, even after multiple uneventful exposures 2

Clinical Presentation

Onset Timing

• MH: Acute onset within 10 minutes to several hours of anesthetic exposure; desflurane may cause more delayed reactions 1
• NMS: Subacute development over 24-72 hours after drug initiation or dose increase 3, 2

Core Features (Both Share)

Both present with hyperthermia, muscle rigidity, autonomic instability, and altered mental status 4, 5

Distinguishing Clinical Characteristics

Malignant Hyperthermia:

• Earliest sign: Unexplained tachycardia with rising end-tidal CO₂ (hypermetabolism) 1
• Masseter spasm after succinylcholine (exaggerated jaw rigidity within 60-90 seconds)
• Rapid temperature rise (can reach >40°C quickly)
• Mixed acidosis (initially respiratory, then metabolic)
• Acute hyperkalaemia from muscle breakdown
• Mottled skin (especially in children), hot and flushed exposed areas 1
• Occurs during active anesthetic exposure

Neuroleptic Malignant Syndrome:

• Lead-pipe rigidity develops before hyperthermia in most cases 6
• Elevated creatine kinase (CK) is earlier and more universal than fever 6
• Temperature rises more gradually to 38-42°C
• Prominent autonomic instability (labile blood pressure, diaphoresis)
• Altered consciousness (confusion, mutism, catatonia) more prominent 2
• Can present without fever initially—rigidity and rising CK are sentinel markers 6

Laboratory Findings

• Both: Elevated CK (often >1000 U/L), myoglobinuria, acute kidney injury risk, metabolic acidosis
• MH: Acute respiratory acidosis from hypermetabolism, rapid hyperkalaemia 1
• NMS: Leukocytosis common, CK elevation may precede fever 6

Pathophysiology

Malignant Hyperthermia:

• Genetic disorder (RYR1 gene mutations most common) affecting skeletal muscle calcium regulation
• Triggering agents cause uncontrolled calcium release from sarcoplasmic reticulum
• Results in sustained muscle contraction and hypermetabolism 1
• Genetic variants have prevalence <1:2000 in general population 1

Neuroleptic Malignant Syndrome:

• Dopamine receptor blockade in central thermoregulatory centers and basal ganglia
• Exact mechanism unclear; may involve altered calcium regulation in susceptible individuals 5
• Not clearly genetic, though susceptibility factors exist 3, 2

Critical Diagnostic Pitfalls

1. Prior uneventful anesthesia does NOT exclude MH risk—patients can receive multiple triggering anesthetics before developing a reaction 1

2. NMS can present without fever initially—do not wait for hyperthermia if rigidity and rising CK are present 6

3. Both conditions can occur in the same patient (rare case reports exist), though they remain distinct entities 7, 8

4. Timing is key: MH occurs during/immediately after anesthesia; NMS develops over hours to days during antipsychotic therapy

Treatment

Malignant Hyperthermia

Immediate actions (mortality 4% with treatment, 70-80% without) 1:

1. Discontinue all triggering agents immediately—this is critical even before dantrolene
2. Dantrolene 2.5 mg/kg IV bolus, repeat every 5 minutes until symptoms resolve (up to 10 mg/kg)
3. Hyperventilate with 100% oxygen (increase minute ventilation 2-3 times)
4. Active cooling measures
5. Treat hyperkalemia aggressively (calcium, insulin/glucose, hyperventilation)
6. Maintain urine output >2 mL/kg/h (prevent myoglobin-induced renal injury)
7. Continue dantrolene 1 mg/kg every 6 hours for 24-48 hours to prevent recrudescence

Neuroleptic Malignant Syndrome

Immediate actions 3, 2:

1. Discontinue all dopamine antagonists immediately
2. Supportive care is primary treatment: aggressive hydration, cooling, benzodiazepines for agitation
3. Dantrolene 1-2.5 mg/kg IV (consider if severe rigidity/hyperthermia)—same mechanism as MH may respond
4. Bromocriptine 2.5-10 mg PO/NG three times daily (dopamine agonist) as adjunct
5. Monitor and treat rhabdomyolysis complications
6. ICU-level monitoring for autonomic instability

Key Treatment Differences

• MH requires dantrolene as specific antidote; early treatment prevents the 4% mortality 1
• NMS treatment is primarily supportive; dantrolene and bromocriptine are adjuncts 3, 2
• Both require immediate discontinuation of triggering agents—this cannot be overemphasized

Prevention

Malignant Hyperthermia:

• Avoid volatile anesthetics and succinylcholine in known/suspected MH-susceptible patients
• Use total intravenous anesthesia (propofol, opioids, non-depolarizing relaxants)
• Consider prophylactic dantrolene only in specific high-risk scenarios (not routine)

Neuroleptic Malignant Syndrome:

• Use lowest effective antipsychotic dose
• Avoid rapid dose escalation or parenteral loading
• Monitor closely during dose changes
• Higher risk with high-potency typical antipsychotics and depot formulations 2

1, 4, 5, 6, 3, 2